Balstilimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, PD-1 monoclonal antibody balstilimab is used for the treatment of cervical cancer, and balstilimab monotherapy and anti-CTLA-4 monoclonal antibody zalifrelimab combined with balstilimab are used to treat metastatic cervical cancer.
Biosimilars
Human
Monoclonal
Human
PDCD1/PD1/CD279
Human
IgG4 Kappa
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
CAS Number 2230167-06-1
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más